XOMA Royalty Corp 8-K — AI Bull & Bear Analysis

The May 21 filing marks a pivotal transition for XOMA as it moves toward integration with Ligand Pharmaceuticals. While the approval of director nominees and the ratification of auditors provide a veneer of stability, the core tension lies between the company's need for aggressive talent acquisition and the shareholders' appetite for dilution. The simultaneous implementation of restrictive bylaw amendments suggests a strategic move to streamline the merger process by limiting legal volatility, though it leaves investors weighing the trade-off between corporate efficiency and shareholder rights.